Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Interventional × PT2385 × Clear all

Phase

Phase 2 2 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 571 pembrolizumab 442 Paclitaxel 410 Gemcitabine 394 Cisplatin 389 Carboplatin 388 Radiotherapy 347 fludarabine 324 Nivolumab 305 Bevacizumab 252 Docetaxel 247 Irinotecan 232 Magnetic Resonance Spectroscopy 217 Fluorouracil 203 Dexamethasone 201 Capecitabine 197 Specimen Handling 196 Rituximab 188 Cytarabine 183 Oxaliplatin 182 Temozolomide 179 fludarabine phosphate 176 Biopsy 175 Ipilimumab 172 Etoposide 166 Lenalidomide 162 Leucovorin 155 Doxorubicin 155 Cetuximab 154 Bortezomib 152

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02293980 2024-06-17

MK-3795-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡